ATLANTA, GA and WARSAW, POLAND --(Marketwired - September 23, 2014) - Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc. (
Warsaw, the financial capital of Central and Eastern Europe, is a major center of life science investment. On October 2nd, at the Global Life Sciences Conference, over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe will gather in Warsaw to discuss and assess new investment opportunities. They will have access there to Perma-Fix Medical's management team through a corporate presentation and small group meetings.
The organizers of this event are: WDM Capital, Wedbush Europe and the Filipex Enterprises. The partners of this event are: Warsaw Stock Exchange, Wedbush, Wierzbowski Eversheds and Crescendo Communications. For more information please visit: http://lscwarsaw.com
About Perma-Fix Medical Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services, a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.
Contacts: David K. Waldman Crescendo Communications Europe S.A. Tel : +1-212-671-1021